ERBB2 and cancer: Luminal B/HER2-positive tumors showed minimal or mild BPE in 11 (79%) and 3 (21%) cases, respectively; HER2-enriched cancers demonstrated moderate enhancement in 1 (25%) case; Triple-negative cancers showed minimal in 2 (67%) and mild in 1 (33%).